Fried Frank acted as counsel to Goldman Sachs, as financial advisor to C.R. Bard in its definitive agreement to be acquired by Becton Dickinson and Company for US$317.00 per Bard common share in cash and stock, for a total consideration of US$24 billion. The combination will create a highly differentiated medical technology company uniquely positioned to improve both the process of care and the treatment of disease for patients and healthcare providers. C.R. Bard is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products. Becton Dickinson and Company is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.
The Fried Frank team included corporate partners Steven Epstein and Philip Richter and included corporate associate Elizabeth Kalenik.